gh-20200806
0001576280false00015762802020-08-062020-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 6, 2020
GUARDANT HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-38683
45-4139254
(State or other jurisdiction
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
505 Penobscot Dr.
Redwood City, California 94063
(Address of principal executive offices) (Zip Code)
855-698-8887
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001
GH
The Nasdaq Global Select Market









Item 2.02. Results of Operations and Financial Condition.
On August 6, 2020, Guardant Health, Inc. (the “Company”) issued a press release announcing certain financial results for the fiscal quarter ended June 30, 2020. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GUARDANT HEALTH, INC.
Date:August 6, 2020
By:/s/ Helmy Eltoukhy
Helmy Eltoukhy
Chief Executive Officer


Document
https://cdn.kscope.io/968cb513098b195cdca30fcc8a52b191-guardantlogoa011.gif
Guardant Health Reports Second Quarter 2020 Financial Results
Q2 2020 Revenue Increase of 23% Over Prior Year Period
REDWOOD CITY, Calif. August 6, 2020 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2020.
Recent Highlights
Revenue of $66.3 million for the second quarter of 2020, an increase of 23% over the corresponding period of 2019
Precision oncology revenue of $51.0 million, an increase of 21% over the corresponding period of 2019
Development services revenue of $15.3 million, an increase of 29% over the corresponding period of 2019
Reported 13,694 tests to clinical customers and 2,805 tests to biopharmaceutical customers in the second quarter of 2020, representing an increase of 15% and a decrease of 47%, respectively, over the second quarter of 2019
Presented data from a new patient cohort that demonstrated that its LUNAR-2 liquid assay achieved 90% sensitivity and 94% specificity in detecting early-stage colorectal cancer
Launched GuardantINFORM, a real-world clinical-genomic platform to accelerate precision oncology drug development
Announced two strategic collaborations to develop the Guardant360 assay as a companion diagnostic for Janssen Biotech’s amivantamab in non-small-cell lung carcinoma, and expanding to a new indication, for Radius Health’s elacestrant in breast cancer
Strengthened financial position with an underwritten public offering raising $354.6 million in net proceeds, ending the second quarter with $1.1 billion cash, cash equivalents and marketable securities
During this challenging time, our team at Guardant Health successfully executed across our business and has never wavered from our commitment to serve patients,” said Helmy Eltoukhy, PhD, co-founder and CEO. “As we look to the second half of this year, despite the ongoing pandemic, I am more confident than ever in the strength and resilience of our team, the promise of the Guardant platform and the significant opportunity ahead to transform patient care.”
Second Quarter 2020 Financial Results
Revenue was $66.3 million for the three months ended June 30, 2020, a 23% increase from $54.0 million for the three months ended June 30, 2019. Precision oncology revenue grew 21% driven predominantly by an increase in average selling price. There were 13,694 clinical tests and 2,805 biopharmaceutical tests performed during the second quarter of 2020. Development services revenue increased 29% primarily related to the timing of project related milestones for companion diagnostic development programs.
Gross profit, or total revenue less cost of precision oncology testing and cost of development services, was $43.9 million for the second quarter of 2020, an increase of $6.8 million from $37.1 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 66%, as compared to 69% for the corresponding prior year period.
Operating expenses were $98.5 million for the second quarter of 2020, as compared to $52.4 million for the corresponding prior year period, an increase of 88%.
Net loss attributable to Guardant Health, Inc. common stockholders was $54.6 million for the second quarter of 2020, as compared to $11.6 million for the corresponding prior year period. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.57 for the second quarter of 2020, as compared to $0.13 for the corresponding prior year period.
Cash, cash equivalents and marketable securities were $1.1 billion as of June 30, 2020. This includes approximately $354.6 million of net proceeds from Guardant Health's follow-on public offering which closed in early June.
2020 Guidance
Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.
Webcast and Conference Call Information
Guardant Health will host a conference call to discuss the second quarter 2020 financial results after market close on Thursday, August 6, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event.

1

https://cdn.kscope.io/968cb513098b195cdca30fcc8a52b191-guardantlogoa011.gif
Non-GAAP Measure
We believe that the exclusion of certain income and expenses in calculating non-GAAP Adjusted EBITDA can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. To derive Adjusted EBITDA, we remove from GAAP results the impact of income (expenses) attributable to material non-cash items, specifically stock-based compensation and fair value remeasurements due to the subjectivity, management judgment, and market fluctuations involved around these amounts. We exclude certain other items because we believe that these income (expenses) do not reflect expected future operating expenses. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance.
This non-GAAP financial measure is not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measure prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.
Definition of Non-GAAP Adjusted EBITDA
“Adjusted EBITDA” is defined as net loss attributable to Guardant Health, Inc. common stockholders before: (i) interest income,(ii) interest expense (iii) provision for (benefit from) income taxes, (iv) depreciation and amortization expense, (v) other (income) expense, net, (vi) stock-based compensation expense, (vii) adjustments relating to non-controlling interest and contingent consideration and, if applicable in a reporting period, and (viii) acquisition-related expenses, and other non-recurring items.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360® and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of Guardant Health’s platforms, assays and tests, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2019 and in its other reports filed with the Securities and Exchange Commission, including, its Quarterly Report on Form 10-Q for the period ended March 31, 2020. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Anna Czene
press@guardanthealth.com



2

https://cdn.kscope.io/968cb513098b195cdca30fcc8a52b191-guardantlogoa011.gif
Guardant Health, Inc.
Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except per share data)
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Revenue:
Precision oncology testing
$50,991  $42,064  $111,237  $70,901  
Development services
15,344  11,911  22,608  19,729  
Total revenue
66,335  53,975  133,845  90,630  
Costs and operating expenses:
Cost of precision oncology testing (1)
17,809  14,650  36,000  25,673  
Cost of development services
4,626  2,183  6,941  4,695  
Research and development expense (1)
36,319  19,532  73,335  35,848  
Sales and marketing expense (1)
25,015  19,439  50,130  37,246  
General and administrative expense (1)
37,186  13,439  56,971  26,100  
Total costs and operating expenses
120,955  69,243  223,377  129,562  
Loss from operations
(54,620) (15,268) (89,532) (38,932) 
Interest income
2,640  3,099  5,958  5,584  
Interest expense
(10) (287) (22) (580) 
Other (expense) income, net
2,285  (51) 2,076  96  
Loss before provision for income taxes
(49,705) (12,507) (81,520) (33,832) 
Provision for (benefit from) income taxes
34  (1,207) 48  (1,181) 
Net loss
(49,739) (11,300) (81,568) (32,651) 
Adjustment of redeemable noncontrolling interest
(4,900) (300) (800) (5,000) 
Net loss attributable to Guardant Health, Inc. common stockholders
$(54,639) $(11,600) $(82,368) $(37,651) 
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
$(0.57) $(0.13) $(0.87) $(0.43) 
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
96,011  89,036  95,196  87,494  
(1) Amounts include stock-based compensation expense as follows:
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Cost of precision oncology testing
$407  $126  $710  $296  
Research and development expense
2,622  1,428  4,986  2,638  
Sales and marketing expense
2,167  646  3,965  1,472  
General and administrative expense20,619  1,015  22,492  1,992  
Total stock-based compensation expense $25,815  $3,215  $32,153  $6,398  
3

https://cdn.kscope.io/968cb513098b195cdca30fcc8a52b191-guardantlogoa011.gif
 Guardant Health, Inc.
Condensed Consolidated Balance Sheets (unaudited)
(in thousands, except share and per share data)
June 30, 2020December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents
$164,671  $143,228  
Short-term marketable securities
773,160  379,574  
Accounts receivable, net
41,017  47,986  
Inventory
20,354  15,181  
Prepaid expenses and other current assets
11,101  11,389  
Total current assets
1,010,303  597,358  
Long-term marketable securities
146,118  268,783  
Property and equipment, net
56,995  43,668  
Right-of-use assets
38,503  29,140  
Intangible assets, net
17,148  8,524  
Goodwill
3,290  3,290  
Capitalized license fees
55  6,890  
Other assets
5,124  4,882  
Total Assets
$1,277,536  $962,535  
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$15,982  $16,197  
Accrued compensation
18,526  18,557  
Accrued expenses
24,055  25,703  
Deferred revenue
11,485  12,277  
Total current liabilities
70,048  72,734  
Long-term operating lease liabilities
41,117  33,256  
Obligation related to royalty
—  6,880  
Other long-term liabilities
1,382  1,672  
Total Liabilities
112,547  114,542  
Redeemable noncontrolling interest
50,400  49,600  
Stockholders’ equity:
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 99,312,237 and 94,261,414 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively
  
Additional paid-in capital
1,544,373  1,150,090  
Accumulated other comprehensive income
5,392  1,111  
Accumulated deficit
(435,177) (352,809) 
Total Stockholders’ Equity
1,114,589  798,393  
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity
$1,277,536  $962,535  

4

https://cdn.kscope.io/968cb513098b195cdca30fcc8a52b191-guardantlogoa011.gif
Guardant Health, Inc.
Reconciliation of Net Loss Attributable to Guardant Health, Inc. Common Stockholders (1) to Non-GAAP Adjusted EBITDA (unaudited)
(in thousands)
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Net loss attributable to Guardant Health, Inc. common stockholders $(54,639) $(11,600) $(82,368) $(37,651) 
Adjustments:
Interest income(2,640) (3,099) (5,958) (5,584) 
Interest expense10  287  22  580  
Other (income) expense, net(2,285) 51  (2,076) (96) 
Provision for (benefit from) income taxes34  (1,207) 48  (1,181) 
Depreciation and amortization3,805  2,657  7,109  5,011  
Stock-based compensation expense25,815  3,215  32,153  6,398  
Adjustments relating to non-controlling interest and contingent consideration
4,900  300  610  5,000  
Acquisition related expenses (2)
—  422  9,707  422  
Adjusted EBITDA (non-GAAP)
$(25,000) $(8,974) $(40,753) $(27,101) 

(1) Net Loss attributable to Guardant Health, Inc. common stockholders is the most directly comparable GAAP operating financial measure.
(2) For the six months ended June 30, 2020, acquisition related expenses consist of a dispute settlement expense of $1.2 million and IPR&D technology write off for $8.5 million incurred for the three months ended March 31, 2020 in connection with a settlement and a license purchase agreement. For the three and six months ended June 30, 2019, acquisition related expenses of $0.4 million primarily include certain diligence, accounting, and legal expenses incurred related to our Bellwether acquisition.
5